Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. is making significant strides in the biopharmaceutical sector with its innovative PREDATOR platform, focused on developing conditionally activated molecules specifically for cancer treatment, which has shown encouraging clinical activities across multiple programs. The company’s lead candidates, WTX-124 and WTX-330, are demonstrating favorable safety profiles with manageable adverse effects and promising anti-tumor activity, suggesting that the platform effectively expands the therapeutic window while mitigating systemic toxicity. With ongoing developments and a potential expansion into other therapeutic areas beyond oncology, Werewolf’s robust portfolio positions it favorably in the evolving landscape of immunotherapy.

Bears say

Werewolf Therapeutics posted a significant net loss of $20.4 million, or $0.46 per share, for the fourth quarter of 2024, representing an increase from a $12.0 million loss in the same quarter the previous year, which raises concerns about its financial sustainability. The company faces risks related to potential clinical or regulatory setbacks linked to WTX-124, as well as challenges in meeting revenue estimates if the product receives approval. Additionally, uncertainties regarding WTX-124's safety, efficacy, and competitive positioning in a landscape of existing and emerging therapies further contribute to a cautious outlook on the stock.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.